{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.5","upperLimit":"22.9","value":"12.4"},{"groupId":"OG001","lowerLimit":"6.5","upperLimit":"19.5","value":"13.4"},{"groupId":"OG002","lowerLimit":"9.3","upperLimit":"21.2","value":"17.6"},{"groupId":"OG003","lowerLimit":"9.3","upperLimit":"20.3","value":"16.9"},{"groupId":"OG004","lowerLimit":"10.4","upperLimit":"20.3","value":"14.0"},{"comment":"The number of events was not sufficient for the estimation of this parameter (i.e. upper limit of the CI)","groupId":"OG005","lowerLimit":"13.1","upperLimit":"NA","value":"22.6"},{"groupId":"OG006","lowerLimit":"8.5","upperLimit":"20.6","value":"16.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"42"},{"groupId":"OG004","value":"42"},{"groupId":"OG005","value":"43"},{"groupId":"OG006","value":"41"}],"units":"Participants"}],"description":"Overall survival is defined as the time from the date of study enrollment to the date of death regardless of cause. For those individuals who have no death reported at the time of the analysis, the censored time at risk will be assessed from the date of study enrollment to the date that the patient was last contacted and known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients randomized to Cedinarib reference arm during the recruitment period (09/04/2018-06/17/2019). Patients receive Cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nCediranib: Given PO\n\nCediranib Maleate: Given PO\n\nComputed Tomography: Undergo CT scan\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA","id":"OG000","title":"Arm I (Cediranib maleate_Referenc Group 1)"},{"description":"Patients receive olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nComputed Tomography: Undergo CT scan\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA\n\nOlaparib: Given PO","id":"OG001","title":"Arm II (Olaparib)"},{"description":"Patients receive olaparib PO BID and cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nCediranib: Given PO\n\nCediranib Maleate: Given PO\n\nComputed Tomography: Undergo CT scan\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA\n\nOlaparib: Given PO","id":"OG002","title":"Arm III (Cediranib Maleate, Olaparib)"},{"description":"Patients receive olaparib PO BID on days 1-28 and capivasertib PO BID on days 1-4 each week. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nCapivasertib: Given PO\n\nComputed Tomography: Undergo CT scan\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA\n\nOlaparib: Given PO","id":"OG003","title":"Arm IV (Olaparib, Capivasertib)"},{"description":"Patients receive olaparib PO BID on days 1-28 and durvalumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nComputed Tomography: Undergo CT scan\n\nDurvalumab: Given IV\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA\n\nOlaparib: Given PO","id":"OG004","title":"Arm V (Olaparib, Durvalumab)"},{"description":"Patients receive cediranib maleate PO QD on days 1-5 each week and durvalumab IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nCediranib Maleate: Given PO\n\nComputed Tomography: Undergo CT scan\n\nDurvalumab: Given IV\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA","id":"OG005","title":"Arm VI (Cediranib Maleate, Durvalumab)"},{"description":"Patients randomized to Cedinarib reference arm during the recruitment period (08/16/2021-06/28/2023).\n\nPatients receive cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nCediranib: Given PO\n\nCediranib Maleate: Given PO\n\nComputed Tomography: Undergo CT scan\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA","id":"OG006","title":"Arm VII (Cediranib maleate_Reference Group 2)"}],"paramType":"MEDIAN","populationDescription":"All patients randomized (Intent-to-Treat)","reportingStatus":"POSTED","timeFrame":"Vital status was assessed every 3 months for 2 years and then every 6 months for 3 years (5-years total).","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}